HeartSciences Inc (HSCSW) Q1 2026 Earnings Report

HeartSciences reported QQ1 2026 results with revenue of $1.9 million and gross profit of $1.14 million, yielding a gross margin of 60%. Reported operating metrics imply a substantial burn, with operating income shown as -$1.874 billion in the income section, while EBITDA is presented as -$1.839 million and net income as -$2.055 million. The apparent discrepancy between the huge operating expense line items (R&D and SG&A reported in the hundreds of millions) and the much smaller EBITDA figure raises data integrity questions that investors should seek clarification on in forthcoming filings. On the cash flow front, the company generated negative operating cash flow of -$1.953 billion but reported large financing activity inflows of $3.648 billion, resulting in a net cash increase of about $1.694 billion and an ending cash balance of $2.792 billion. These dynamics suggest a cash runway predominantly driven by financing activity rather than operating cash generation.

Market position remains that of a niche cardiovascular diagnostics companycommercializing a resting 12-lead ECG platform (MyoVista wavECG). The QQ1 2026 results indicate early-stage revenue traction but a cost structure that far outpaces revenue, implying a high burn rate unless revenue growth accelerates meaningfully. The data also contain evident inconsistencies across balance sheet items (e.g., total current liabilities vs. debt levels) that warrant careful verification in the 10-Q/annual report. Investors should monitor execution milestones (clinical adoption, reimbursement pathways, and partnership deals) and any management commentary clarifying cost structure and non-cash items in future disclosures.